CTI Licenses New Form Of Paclitaxel
Cell Therapeutics Inc has licensed the rights to polyglutamic acidpaclitaxel (PG-TXL), a water-soluble form of Bristol-Myers Squibb's best-selling anticancer drug Taxol (paclitaxel), from the University of Texas' M D Anderson Cancer Center in the USA.
The new compound consists of paclitaxel chemically-bonded to a polymer of glutamic acid. In a recent paper published in Cancer Research, PG-TXL significantly delayed tumor growth in ovarian and breast cancer animal models compared with similar doses of Taxol. In preclinical animal testing, PG-TXL had a 100% increase in the maximum tolerated dose of paclitaxel, and the suggestions are that it may be administered quickly, in minutes rather than hours as is required with Taxol.
CTI said that it wanted to bring PG-TXL to the clinic as quickly as possible, with probable first indications being breast, lung and colon cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze